Skip to content
← Full study record

NCT00103610 · OUTCOME

Graft Durability at 100 Days Post Transplantation

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients · Source last updated 2014-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion of participants
Interval / dispersion
Not reported
Time frame
approximately Day 138

What was measured

The proportion of participants maintaining a durable graft at 100 days post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

Analysis population: Participants who received a stem cell transplant and were evaluable at 100 days post-transplant

Groups in this outcome

G-CSF Plus Plerixafor

Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of plerixafor. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of plerixafor for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

G-CSF Plus Placebo

Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of placebo. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of placebo for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
G-CSF Plus Plerixafor135
G-CSF Plus Placebo82

Reported measurements

Proportion of participants with durable graft
Values in proportion of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
G-CSF Plus Plerixafor0.948Not reportedNot reportedNot reportedNot reported
G-CSF Plus Placebo0.951Not reportedNot reportedNot reportedNot reported
Proportion of participants without durable graft
Values in proportion of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
G-CSF Plus Plerixafor0.052Not reportedNot reportedNot reportedNot reported
G-CSF Plus Placebo0.049Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0.948
      2. group Id
        OG001
        value
        0.951
    title
    Proportion of participants with durable graft
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0.052
      2. group Id
        OG001
        value
        0.049
    title
    Proportion of participants without durable graft
denoms
  1. counts
    1. group Id
      OG000
      value
      135
    2. group Id
      OG001
      value
      82
    units
    Participants
description
The proportion of participants maintaining a durable graft at 100 days post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.
groups
  1. description
    Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of plerixafor. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of plerixafor for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
    id
    OG000
    title
    G-CSF Plus Plerixafor
  2. description
    Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of placebo. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of placebo for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
    id
    OG001
    title
    G-CSF Plus Placebo
param Type
NUMBER
population Description
Participants who received a stem cell transplant and were evaluable at 100 days post-transplant
reporting Status
POSTED
time Frame
approximately Day 138
title
Graft Durability at 100 Days Post Transplantation
type
SECONDARY
unit Of Measure
proportion of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice